DAM
ACOR

DLD Asset Management’s Acorda Therapeutics ACOR Stock Holding History

DLD Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,349
Closed -$5.92M – 103
2017
Q1 		$5.92M Buy
2,349
+1,220
+108% +$3.51M 0.95% 19
2016
Q4 		$2.55M Buy
+1,129
New +$2.68M 0.83% 20

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DLD Asset Management's ACOR Position: Q2 2017 in Review

DLD Asset Management sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 2,349 shares — an estimated $5.92M sold.

DLD Asset Management first reported a position in ACOR in Q4 2016 and held it in 2 quarters. The position peaked at $5.92M in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • DLD Asset Management reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • DLD Asset Management sold 2,349 Acorda Therapeutics shares in Q2 2017, an estimated $5.92M.
  • DLD Asset Management first reported a position in Acorda Therapeutics in Q4 2016 and held it in 2 quarters.
  • DLD Asset Management's Acorda Therapeutics position peaked at $5.92M in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on DLD Asset Management's 13F filing for Q2 2017, filed 11 Aug 2017.